Survodutide

Survodutide (BI 456906) is an investigational injectable peptide that activates two metabolic receptors at once: the GLP-1 receptor, which helps lower appetite, and the glucagon receptor, which raises energy expenditure and changes how the liver processes fat ¹. It is in phase 3 development for obesity, obesity with type 2 diabetes, and fatty liver disease, specifically metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) ¹.

The molecule is a synthetic 29-amino-acid peptide built from a glucagon backbone with selected amino acids from GLP-1 and exendin-4, plus a fatty acid tail that extends its time in the body and supports once-weekly dosing ¹⁶. In published phase 3 data, once-weekly doses of 3.6 mg and 6.0 mg produced mean weight loss of 12.2% and 13.0% at 76 weeks, versus 5.4% with placebo ¹.

Liver studies are a second major focus. In the phase 3 SYNCHRONIZE-MASLD trial, 84.2% of participants receiving 6.0 mg weekly achieved at least a 30% reduction in MRI-assessed liver fat at 48 weeks, versus 24.3% with placebo ⁴. Earlier phase 2 work reported histological improvement in MASH with liver fibrosis ⁵.

Survodutide pairs two receptor actions that work on different parts of metabolism.

Two receptors, one peptide

GLP-1 receptor activation suppresses appetite and slows stomach emptying. Glucagon receptor activation increases energy expenditure and drives lipid oxidation in the liver ¹⁷. The pairing is why survodutide produced greater weight loss than a GLP-1-only agent in direct comparisons: in a 16-week type 2 diabetes trial, survodutide reduced body weight by up to 8.7% versus 5.3% for semaglutide 1.0 mg ³.

The peptide backbone is derived from glucagon, with three positions swapped to GLP-1 sequence, one position from exendin-4, and a C18 fatty diacid at Lys24 to bind albumin ¹⁶. In assay conditions that include albumin, potency is about 8-fold higher at the GLP-1 receptor than the glucagon receptor ¹⁶.

Why the glucagon side matters

At the glucagon receptor, survodutide recruits less beta-arrestin and triggers less receptor internalization than native glucagon, which is proposed to prolong signaling in the liver ¹⁶. Animal data point the same direction: in diet-induced obese mice at thermoneutrality, survodutide reduced body weight by 32% versus 27% for semaglutide, with a transient increase in energy expenditure while food intake suppression was similar ¹⁹. Brain studies show action through circumventricular organs and activation of appetite-related neuronal regions ²⁹. Hepatic glucagon receptors appear essential, because deleting them in mice removed the superior weight loss of a closely related analog ³⁰.

Human biomarker analyses show improvements in beta-cell function and insulin sensitivity, including higher HOMA-B and lower HOMA-IR, fasting insulin, and glucagon, largely independent of weight loss ¹¹.

Survodutide's documented effects come mainly from randomized controlled trials, with mechanistic support from animal and laboratory work.

Effect	What the research shows	Evidence
Body weight	-14.9% at 4.8 mg weekly versus -2.8% placebo at 46 weeks	Phase 2 RCT 2
Body weight, phase 3	-12.2% at 3.6 mg and -13.0% at 6.0 mg versus -5.4% placebo at 76 weeks	Phase 3 RCT 1
Glycemic control	HbA1c fell up to 1.71% from baseline at 16 weeks in type 2 diabetes, versus 1.47% for semaglutide	Phase 2 RCT 3
Liver fat	84.2% achieved at least 30% MRI-liver-fat reduction at 48 weeks, versus 24.3% placebo	Phase 3 RCT 4
MASH histology	Fibrosis improvement in F2-F3 MASH was largely weight-independent in mediation analysis	Phase 2 RCT 5
Cardiometabolic markers	Systolic blood pressure fell up to 10.2 mmHg and diastolic up to 4.8 mmHg, with reductions in triglycerides and waist circumference	Phase 2 post hoc 13
Energy expenditure	Increased transiently in obese mice versus semaglutide, with comparable food intake suppression	Animal 19

Meta-analyses place pooled weight loss around 6.7 kg and waist reduction around 7.09 cm versus placebo, with greater effects at weekly doses above 2.4 mg and durations beyond 16 weeks ⁹. A network meta-analysis ranked survodutide 6 mg weekly first among tested interventions for MASH resolution without fibrosis worsening ⁷.

Human lean-mass preservation is not yet established; preclinical work found preserved muscle weight and grip strength relative to semaglutide in mice ¹⁹, and an MRI body-composition substudy was preplanned ²⁶.

Published survodutide protocols use once-weekly subcutaneous dosing. The phase 2 obesity trial used a 20-week escalation followed by 26 weeks of maintenance, testing 0.6, 2.4, 3.6, and 4.8 mg weekly ². Phase 3 trials dose-adjust to 3.6 mg or 6.0 mg weekly, with flexibility permitted for tolerability; the Chinese phase 3 program instead used 3.6 mg or 4.8 mg weekly ¹. In type 2 diabetes, a 16-week phase 2 trial tested weekly doses up to 1.8 mg, plus twice-weekly arms at 1.2 mg and 1.8 mg ³. Early phase 1 work examined escalation to 1.8 mg or 4.8 mg weekly, or 2.4 mg twice weekly ¹⁴.

Meta-analyses point to 2.4-4.8 mg once weekly as the effective clinical window ⁹. Doses above 2.4 mg weekly outperformed lower doses for HbA1c, body weight, and waist circumference, and benefits grew with treatment longer than 16 weeks ⁹. Because gastrointestinal adverse events cluster during escalation, slow, tolerance-guided titration is the main way trials manage tolerability ¹.

Trial setting	Regimen	Duration
Phase 3 obesity, no diabetes	3.6 or 6.0 mg weekly	76 weeks 1
Phase 2 obesity dose-finding	0.6-4.8 mg weekly	46 weeks 2
Phase 2 type 2 diabetes	up to 1.8 mg weekly, or 1.2/1.8 mg twice weekly	16 weeks 3
Phase 3 obesity with MASLD	6.0 mg weekly	48 weeks 4

No published protocol uses weight-based dosing; trial doses are fixed ¹. Published durations reach 76 weeks, and no scheduled off-period appears in any trial design ¹.

Clinical survodutide trials used manufacturer-prepared solution, so no published trial protocol describes user reconstitution ¹. For research-grade lyophilized peptide, standard handling guidance applies.

• Bacteriostatic water is the standard diluent for reconstitution.
• Inject the diluent slowly down the vial wall, then swirl gently. Avoid shaking or vortexing: the acyl side chain makes the peptide surface-active, and vigorous agitation can cause foaming and aggregation ².
• Refrigerate reconstituted solution at 2-8°C and use it within roughly 28-30 days. Do not freeze after reconstitution.
• Lyophilized powder can be stored at -20°C long term, or at 2-8°C for shorter periods, kept dry and protected from light.
• For multi-dose vials, swab the stopper with alcohol before each draw and use a new sterile needle and syringe.

The calculator below converts between vial amount, diluent volume, and the dose in milligrams. Discard any solution that becomes cloudy, discolored, or contains particles.

No dedicated clinical drug-interaction program has been published for survodutide, so the interaction picture comes from phase 1 pharmacodynamic probes, trial background-therapy rules, and receptor pharmacology ¹⁴.

Combination	What the research indicates
Sulfonylureas or prandial insulin	Additive hypoglycemia risk as glucose control improves; HbA1c fell by 1.71% in a 16-week diabetes trial 3. Trialists reduce these background therapies prospectively during dose escalation.
Metformin	Established background therapy in trials; continue, with attention to overlapping GI effects 3.
Narrow-therapeutic-index oral drugs	Transient delayed gastric emptying in week 1 reduced paracetamol absorption, so absorption of drugs such as warfarin, digoxin, or levothyroxine may shift 14.
Antihypertensives	Blood-pressure lowering can be additive; systolic reductions reached 10.2 mmHg in a phase 2 analysis 13.
Heart-rate-affecting drugs	Survodutide raises heart rate to a degree similar to GLP-1 monoagonists 20.
Alcohol	A preclinical hamster model showed strongly reduced voluntary alcohol intake, while GI irritation and dehydration are additive in humans 42.

No human combination studies support stacking survodutide with another GLP-1 receptor agonist; shared mechanism and GI burden argue against it ¹. The only positive peptide-peptide combination in the evidence base is preclinical: adding the investigational NPY2R agonist BI 1820237 increased weight loss in obese mice from 17% to 22% ⁴¹.

Supplements that add GI load, such as fiber or berberine, may compound nausea during escalation; stimulant and thermogenic supplements can add heart-rate burden ²⁰. Electrolyte replacement during vomiting and diarrhea is a practical safeguard ¹.

Published survodutide trials have not tested deliberate on-and-off cycling. Regimens in the evidence base are continuous: 16 weeks in the type 2 diabetes trial, 46 weeks in the phase 2 obesity trial, 48 weeks in SYNCHRONIZE-MASLD, and 76 weeks in SYNCHRONIZE-1 ¹. Weight loss had not plateaued by week 46 in the phase 2 trial ², and phase 3 treatment-regimen estimates show that benefit depends on continued treatment ¹. No published protocol includes scheduled off-periods.

A few findings inform the cycling debate without settling it. Survodutide shows biased agonism at the glucagon receptor, with less beta-arrestin recruitment and less internalization than native glucagon, which may prolong signaling rather than desensitize it ¹⁶. Its energy-expenditure increase in mice is transient, peaking early and fading during continuous dosing ¹⁹. Gastrointestinal adverse events are dose-dependent and concentrated during escalation ¹.

Community research discussions sometimes describe an induction block, a 4-8 week washout, and re-initiation from a low dose, but this pattern has no controlled human evidence. Because tolerance builds during escalation and is lost after a break, trial templates re-start low and re-escalate slowly ¹⁴. A dosing lapse longer than two weeks generally calls for starting again at a low step rather than resuming a maintenance dose ¹⁴.

No human multi-peptide stack has been studied in the published survodutide program. Most combination evidence is preclinical or theoretical.

• NPY2R agonist BI 1820237: the only demonstrated positive peptide combination. Adding it to survodutide increased weight loss from 17% to 22% in diet-induced obese mice ⁴¹. It is investigational and not a routine research option.
• Other GLP-1-based agents: no human combination data exist for survodutide with semaglutide, liraglutide, tirzepatide, or retatrutide. These share the GLP-1 receptor mechanism and would be expected to add gastrointestinal burden ¹.
• Amylin analogs: cagrilintide or pramlintide act on a different appetite circuit, so additivity is plausible, but there are no survodutide-specific data.
• Growth hormone secretagogues: growth hormone can oppose insulin action, so combinations with tesamorelin, ipamorelin, or sermorelin would need glucose monitoring (theoretical).
• BPC-157 or TB-500: no interaction data exist. Some community protocols add them for gut tolerance during titration, but this is unproven.

Preclinical work also explored survodutide with alcohol intake reduction ⁴², and separate studies are testing survodutide in heart failure and stroke models, but those are monotherapy studies, not stacks ³⁶.

Survodutide is investigational and is not FDA-approved for any indication. It is absent from the current list of six FDA-approved long-term obesity therapies: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide, and tirzepatide ²⁵. Published phase 3 data cover obesity and obesity with MASH/MASLD, but no marketing authorization is reported ¹.

Registration-track trials are completed or ongoing, including SYNCHRONIZE-2 for obesity with type 2 diabetes, SYNCHRONIZE-CN in China, SYNCHRONIZE-JP in Japan, and the SYNCHRONIZE-CVOT cardiovascular outcomes trial ²². The LIVERAGE phase 3 trial is investigating MASH with F2-F3 fibrosis ⁵¹.

Because no approved or marketed formulation exists, there is no established lawful compounding or personal-import pathway for this molecule. No DEA scheduling and no WADA or anti-doping-body determination specific to survodutide appear in the published literature.

The main safety signal in trials is dose-dependent gastrointestinal adverse events during dose escalation.

Adverse effect	What trials report
Nausea, vomiting, diarrhea	80.9% at 3.6 mg and 89.7% at 6.0 mg had any GI adverse event in SYNCHRONIZE-1, versus 47.9% with placebo 1.
Decreased appetite	Reported in 66.7% of active-dose participants in a phase 1 study; a leading cause of withdrawal during escalation 14.
Discontinuation due to adverse events	24.6% versus 3.9% with placebo in the 46-week phase 2 obesity trial 2.
Heart rate	Increases to a degree similar to GLP-1 receptor monoagonists, while blood pressure falls 13.
Pancreatic enzymes	Transient amylase elevation reported; one phase 1 withdrawal for amylase increase 14.
Serious adverse events	No significant excess versus placebo in pooled analyses 9.

Fast titration appears to drive discontinuations: the phase 2 obesity trial used rapid bi-weekly escalation and concentrated GI events during that window ². Slower escalation is the main mitigation used in later trial designs ¹.

A thorough QT study is ongoing because another glucagon/GLP-1 dual agonist was discontinued partly for heart-rate increase and QT prolongation ²⁰. Long-term safety beyond 76 weeks, human pregnancy and lactation data, and post-treatment durability are not yet published ¹.